title: Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors.
abstract: OBJECTIVE
  Elevated total serum cholesterol levels have been reported recently in a group of patients with metastatic testicular cancer after treatment with cisplatin combination chemotherapy. We have studied the lipid profile of a similar group of patients in an attempt to confirm this observation.
  
  
  METHODS
  Fasting plasma lipid concentrations were measured in 47 patients with advanced germ cell tumors who were previously treated with a cisplatin combination chemotherapy. The values obtained for mean total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, apolipoprotein A1, and apolipoprotein B concentrations were compared with those obtained from a control group of 59 patients with germ cell tumors who were not treated with chemotherapy and with data from the New Zealand male population. Median time from the completion of chemotherapy to lipid measurement in the treated group was 50 months (range, 2 to 138 months). The median total dose of cisplatin given was 720 mg (range, 300 to 1,625 mg).
  
  
  RESULTS
  Mean total plasma cholesterol concentrations in the cisplatin group (5.87 mol/L) and the control group (5.70 mmol/L) did not differ significantly (P > .4). There was no significant difference for any of the variables between the chemotherapy and control groups and those of the New Zealand male population. There was a trend toward higher mean triglyceride concentrations in the chemotherapy group, but this did not reach significance.
  
  
  CONCLUSIONS
  We have not demonstrated an elevation in total plasma cholesterol after cisplatin chemotherapy as has been reported by previous investigators. Our results suggest that in these patients, cisplatin-containing combination chemotherapy is not associated with a significant adverse effect on plasma lipid profile.
authors.affiliation: Department of Oncology, Christchurch Hospital, New Zealand.
authors.forename: P A
authors.initials: PA
authors.lastname: Ellis
authors.forename: B M
authors.initials: BM
authors.lastname: Fitzharris
authors.forename: P M
authors.initials: PM
authors.lastname: George
authors.forename: B A
authors.initials: BA
authors.lastname: Robinson
authors.forename: C H
authors.initials: CH
authors.lastname: Atkinson
authors.forename: B M
authors.initials: BM
authors.lastname: Colls
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005215:Fasting; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000097:blood* / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D002945:Cisplatin